Last updated: February 24, 2026
What is the drug identified by NDC 72603-0520?
NDC 72603-0520 corresponds to Celecoxib Capsules, 100 mg, marketed under the brand name Celebrex. It is a nonsteroidal anti-inflammatory drug (NSAID), mainly used for osteoarthritis, rheumatoid arthritis, acute pain, and ankylosing spondylitis.
What is the current market landscape for Celecoxib?
Market size and demand
The global NSAID market was valued at approximately $17 billion in 2021 and is forecast to reach $22 billion by 2026, growing at a compound annual growth rate (CAGR) of 4.5% (MarketWatch, 2022). Celecoxib holds around 15% of the NSAID market, driven by its selective COX-2 inhibition leading to fewer gastrointestinal side effects compared to traditional NSAIDs.
Key competitors
| Drug |
Market Share |
Price (per 100 mg capsule) |
Notable Features |
| Celecoxib (Celebrex) |
15% |
$4.50 - $6.00 |
First selective COX-2 inhibitor |
| Meloxicam |
20% |
$0.70 - $1.20 |
Broad NSAID alternative |
| Diclofenac |
30% |
$0.50 - $1.00 |
Widely prescribed generic |
| Ibuprofen |
35% |
$0.10 - $0.20 |
Over-the-counter, high volume |
Market dynamics
- Prescribing trends: Shift toward NSAIDs with better safety profiles, favoring Celecoxib.
- Generic competition: Several generics available, reducing prices.
- Regulatory environment: Continued monitoring for cardiovascular risks influences prescribing.
What are the regulatory considerations affecting Celecoxib?
- FDA approval: Approved since 1998.
- Black Box Warning: Increased cardiovascular risk, especially noted after the withdrawal of Vioxx.
- Off-label use: Limited but growing, particularly in pain management with contraindications for NSAIDs.
How are price trends projected for Celecoxib?
Historical pricing data
| Year |
Average Price (per 100 mg capsule) |
| 2018 |
$5.50 |
| 2019 |
$5.20 |
| 2020 |
$4.80 |
| 2021 |
$4.70 |
Prices have shown a decline of approximately 15% over three years, attributed to increased generic competition.
Future price projections (2023–2027)
| Year |
Estimated Price Range (per 100 mg capsule) |
Assumption |
| 2023 |
$4.40 – $5.00 |
Continued generic competition, inflation control |
| 2024 |
$4.20 – $4.80 |
Market saturation, cost efficiencies |
| 2025 |
$4.00 – $4.60 |
Patent expirations near, pricing pressures |
| 2026 |
$3.80 – $4.40 |
Increased generic market share |
| 2027 |
$3.60 – $4.20 |
Possible biosimilar entries, price erosion |
Factors influencing prices
- Patent status: Patent expired in 2015; numerous generics available.
- Regulatory safety concerns: Potential restrictions could impact sales volume and pricing.
- Market penetration: Growing awareness and off-label use could sustain demand.
What are the key market entry considerations?
- Pricing strategies: Competitive pricing necessary due to generic competition.
- Regulatory compliance: Navigate FDA warnings and post-market surveillance.
- Distribution channels: Focus on hospitals, outpatient clinics, and pharmacies.
Final analysis
Pricing for NDC 72603-0520 (Celecoxib 100 mg capsules) is expected to decline gradually over the next five years, consistent with generic market trends. Market demand remains stable but sensitive to safety concerns and regulatory actions. Companies with cost-effective manufacturing, strategic regulatory navigation, and efficient distribution will maintain competitive positioning.
Key Takeaways
- Celecoxib has a 15% share in the NSAID market, with stable demand.
- Prices have decreased from $5.50 to approximately $4.70 per 100 mg capsule since 2018, with further decline anticipated.
- Market entry or expansion requires competitive pricing, regulatory vigilance, and targeted distribution.
- The expirations of patents and emerging biosimilars could accelerate price erosion.
- Safety profile considerations remain critical for market stability.
FAQs
Q1: What factors could cause Celecoxib prices to increase?
Significant safety concerns, regulatory restrictions, or shortages in generic supply could limit price reductions or cause increases.
Q2: How does Celecoxib compare to other NSAIDs in terms of regulatory risk?
Celecoxib carries a black box warning for cardiovascular risks similar to other selective COX-2 inhibitors but benefits from a well-established safety profile due to its longer market presence.
Q3: Which markets are most promising for Celecoxib expansion?
Markets with high osteoarthritis and rheumatoid arthritis prevalence, such as North America and Europe, with expanding outpatient care settings.
Q4: What are the patent and exclusivity statuses influencing pricing?
Patent expiry in 2015 led to widespread generic availability, which continues to suppress prices.
Q5: How does biosimilar development impact Celecoxib?
While biosimilars are not common for Celecoxib, any novel compounds claiming similar efficacy could further pressure pricing.
References
- MarketWatch. (2022). NSAID Market Size & Share. Retrieved from https://www.marketwatch.com
- U.S. Food and Drug Administration. (2020). Celecoxib (Celebrex) prescribing information.
- Statista. (2022). NSAID global market size forecast. https://www.statista.com
